miRview meso

Home > miRview meso: Patients and Caregivers > miRview meso

Differentiating clearly helps
you make informed decisions

miRview® meso is a cutting-edge molecular diagnostic test that uses microRNA
to differentiate malignant pleural mesothelioma from peripheral adenocarcinomas
of the lung or metastatic carcinomas involving the lung pleura.

Introducing miRview® meso

miRview® meso accurately differentiates malignant pleural mesothelioma from other carcinomas in the lung and pleura

Many cancer diagnostics are associated with significant challenges, including suboptimal sensitivity and specificity¹ and low concordance levels². Unlike the tests currently available, miRview® meso is a microRNA-based molecular diagnostic tool that provides a differential diagnosis with:

Accuracy
Simple interpretation
Routine sample preparation

miRview® meso delivers quality results

The miRview® meso assay uses quantitative real-time PCR (qRT-PCR) to determine the expression of microRNA in tumor tissue. The sensitivity and specificity of this assay have been shown to be 100% and 94%, respectively³.

miRview® meso is easy to use

miRview® meso is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the post-op setting. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.

Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin.
Nat Biotechnol. 2008;26(4):462-469.
Stang A, Pohlabeln H, M?ller KM, Jahn I, Giersiepen K, J?ckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
Data on file, Rosetta Genomics.